期刊
DIAGNOSTIC AND INTERVENTIONAL IMAGING
卷 101, 期 9, 页码 577-588出版社
ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.diii.2020.02.004
关键词
Antigen presenting cell (APC); Fluorine-19 (19F); Cellular magnetic resonance imaging (MRI); Cancer immunotherapy
资金
- Ontario Institute for Cancer Research Smarter Imaging Program [R4174419]
- Foundation Grant for Prostate Cancer Research [R2417A21]
- Dendreon Corporation [Proof of Concept Project] [R2417A20]
Purpose. - The purpose of this study was to test fluorine-19 (19F) cellular magnetic resonance (MRI) as a non-invasive imaging modality to track therapeutic cell migration as a surrogate marker of immunotherapeutic effectiveness. Materials and methods. - Human peripheral blood mononuclear cell- (PBMC)-derived antigen presenting cell (APC) were labeled with a 19F-perfluorocarbon (PFC) and/or activated with granulocyte macrophage colony-stimulating factor (GM-CSF). Viability, phenotype and cell lineage characterization preceded 19F cellular MRI of PFC+ PBMC under both pre-clinical 9.4 Tesla (T) and clinical 3T conditions in a mouse model. Results. - A high proportion of PBMC incorporated PFC without affecting viability, phenotype or cell lineage composition. PFC+ PBMC were in vivo migration-competent to draining and downstream lymph nodes. GM-CSF addition to culture increased PBMC migration to, and persistence within, secondary lymphoid organs. Conclusion. - 19F cellular MRI is a non-invasive imaging technique capable of detecting and quantifying in vivo cell migration in conjunction with an established APC-based immunotherapy model. 19F cellular MRI can function as a surrogate marker for assessing and improving upon the therapeutic benefit that this immunotherapy provides. (C) 2020 L'Auteur(s). Publie par Elsevier Masson SAS au nom de Societe francaise de radiologie.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据